Driving home from your office, I could see my wife sitting next to me in the car, not just her hand on the steering wheel. There were cows by the side of the road. I could even see what color they were. My night vision improved, too. 57 year old man with retinitis pigmentosa.

Retinal Protective Therapy (RPT) improves the health and function of the retina in virtually every situation. This includes retinal diseases that are inherited. 

“Now I can see the utensils in the kitchen drawer, and not have to feel around for them like I used to. I could see and recognize people’s faces at a party. I haven’t been able to do that for years. The other day, I ran late and was able to drive comfortably at dusk instead of calling someone to come get me.” 60 year old woman with Stargardt’s.

Retinitis pigmentosa results from one of more than 150 possible gene abnormalities that lead to gradual loss of peripheral vision, night vision, and eventually all vision.  In Stargardt’s disease and Cone Degenerations, the inheritance and gene abnormalities are entirely different. In these, blindness is rare; but legal blindness (loss of central vision) is common.

“Everything is brighter and sharper. I can read better on my ipad.” 45 year old man with Usher’s syndrome.

In each of these inherited retinal degenerations – Retinitis Pigmentosa, Stargardt’s Disease, Cone Degeneration, and others – RPT Retinal Activation improves retinal health and function. By so doing, progression of the disease can be slowed or stopped, and the risk of vision loss reduced. In fact, by restoring function to parts of the retina not previously working, RPT Retinal Activation actually reverses the disease process. Visual fields, night vision, and visual acuity can be improved; often to levels not previously enjoyed for many years.  

Most patients notice improved vision within 24 hours after treatment, and these improvements can be confirmed by testing. By 6 weeks, most also note that the treatment improvements begin to wear off. This is faster than in other retinal diseases. However, by repeating treatment every 6-12 weeks, the improvements can be maintained and even increase, for years. Thus, the benefits of RPT Retinal Activation in RP are significant, and can increase with time. 

“That night I could see stars again for the first time and 10 years. When I got home, I could walk through the house without all of the lights on.” 27 year old woman with retinitis pigmentosa.



Stargardt’s Disease

Visual field tests of patient with Stargardt’s disease. Left side, before SDM RPT. Right side, one month after SDM RPT. Note improvement in visual function by all testing indices.

Retinits Pigmentosa

How RP affects vision

How things look with Stargardt’s disease.

Visual field test of patient with RP before (left) and 2 weeks after (right) RPT. “Driving home, I could see stars for the first time in 10 years. When I got home, I could walk through the house without every light on.”

Visual field test before (left) after (right) RPT for RP.
Note enlargement of the visual area.

Visual field test before (left) and 2 weeks (right) after RPT for Stargardt’s disease. “Everything is clearer and brighter. I can recognize faces again at parties. I can see utensils in the kitchen drawer again, without feeling for them. I was able to drive at dusk for the first time in years.”

This patient with RP returned 18 months after initial RPT, reporting that the treatment was wearing off in his left eye. RPT was repeated. Visual field before (left) and one day after (right) retreatment with RPT. “My peripheral vision and night vision came right back”.

The scientific paper “Improved retinal and visual function following panmacular subthreshold diode micropulse laser (SDM) in retinitis pigmentosa” published February 15, 2018 in the journal Eye,  is the first to report clinically effective treatment for RP.

The results of this small controlled study are robust and highly significant. We would like to perform a larger, nationwide study to confirm these findings and increase the availability of this very important treatment to all those with RP who might benefit. Please contact Dr. Luttrull if you, or your organization, have the interest and ability to sponsor / fund this very important study.

Should you wait for treatment until such a “randomized prospective clinical trial” is completed? Even if such a study were begun tomorrow, the results would not be available for several years. The safety of SDM RPT, the published results, and the rapidly progressive nature of RP suggest it is reasonable to begin treatment now.